Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
Vera Ignjatović, Founder and Managing Director at Ignis Innovations Pty Ltd, Principal Consultant of Translational Research at Johns Hopkins All Children’s Hospital, shared on LinkedIn about a recent article she and her colleagues co-authored, published in JTH, adding:
“Children with blood clots deserve better, and that starts with drugs actually designed and tested for them.
The truth is, most antithrombotic drugs children receive today were developed for adults.
Heparins and warfarin have been the backbone of treatment for over half a century, with a wave of newer agents opening new possibilities.
The critical question is: how do we rigorously study these drugs in children to understand their true benefits and risks?
Our new guidance paper provides expert guidance on exactly that – the rigorous study of antithrombotic drugs, from trial design and endpoint selection to regulatory strategy and real-world effectiveness.
Behind this work is a growing international community (Pedi-ATLAS and the ISTH Pediatric/Neonatal SSC) committed to ensuring that pediatric patients never simply an afterthought in drug development.
Because children are Not small adults.
They deserve science built for them!
‘Development of New Antithrombotic Drugs for Children (Part ), guidance from the International Society on Thrombosis and Haemostasis (ISTH) Scientific Standardization Committee Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group’ ”
Title: Development of new antithrombotic drugs for children (part ): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group
Authors: Neil A. Goldenberg, Scott D. Berkowitz, Marisol Betensky, Susanne Holzhauer, Vera Ignjatovic, Amy Kiskaddon, Daniel Schaufelberger, Paul Monagle, Christoph Male
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026